Sign Up for Mailing List   Contact Us   Advertise    Request Reprints of Articles

NJLawman.com
N E W S,  O P I N I O N,  C O M M E N T A R Y
                                          
 

       L A W   E N F O R C E M E N T   M A G A Z I N E


2014 NJ Police Training & Schools

Police and Fire Mortgage Rate...  3.68 %! 

Call Sharon Press or Andi Pasquin at
(866) 612-1864 for this and other
mortgage products or click here for flyer.

Current
Police & Fire
Mortgage Rate

Visit Us on Facebook

Follow Us on Twitter

Visit
Our
2014
NJ
Police Training
&
Schools Section

 

Features

Home

NJ Law Enforcement

Site Search

Editorials

Roll Call

Opinions

Photo of the Week

Links

Site Map

 

News

Police News

News Archives Nation

News Archives NJ

L/O Duty Deaths

Events

 

Marketplace

LE Equipment

LEO Gifts

 

Click here to receive NJ Law Enforcement Bulletins

 

Training

NJ Police Training

National Training

 

Resources

Invest Resources

NJ Media Center

10 Deadly Sins

NJ Newspapers

Comp Time Law

NJ Most Wanted

Police Videos

Entry Level

Links

Police Poems

National Police Week

 

IA

IA Resource Center

Garrity Warning

 

Forums

Forums

 

NJLawman.com

About Us & Info

Advertise

Contact Us

Contact Us

 

Satellite Phones  An Asset
for Disasters

 

 

OFFICERS USING VIOXX AS A
PAIN MEDICATION, STOP!

 

If you or any of the officers in your agency are using the prescription drug, Vioxx, stop!

Vioxx is often used for Arthritis and as a pain medication.  Obviously, law enforcement officers are no strangers to pain medication.

The drug was voluntarily recalled by its manufacturer, Merck.  According to the FDA, the the drug may result in an increased risk of serious cardiovascular events, including heart attacks and strokes, among study patients taking Vioxx compared to patients receiving placebo.

Below is the press release regarding Vioxx as issued by the FDA last month:

 

FDA Issues Public Health Advisory on
Vioxx as its Manufacturer Voluntarily Withdraws the Product

The Food and Drug Administration (FDA) today acknowledged the voluntary withdrawal from the market of Vioxx (chemical name rofecoxib), a non-steroidal anti-inflammatory drug (NSAID) manufactured by Merck & Co. FDA today also issued a Public Health Advisory to inform patients of this action and to advise them to consult with a physician about alternative medications.

Merck is withdrawing Vioxx from the market after the data safety monitoring board overseeing a long-term study of the drug recommended that the study be halted because of an increased risk of serious cardiovascular events, including heart attacks and strokes, among study patients taking Vioxx compared to patients receiving placebo. The study was being done in patients at risk of developing recurrent colon polyps.

"Merck did the right thing by promptly reporting these findings to FDA and voluntarily withdrawing the product from the market," said Acting FDA Commissioner Dr. Lester M. Crawford. "Although the risk that an individual patient would have a heart attack or stroke related to Vioxx is very small, the study that was halted suggests that, overall, patients taking the drug chronically face twice the risk of a heart attack compared to patients receiving a placebo."

Dr. Crawford added that FDA will closely monitor other drugs in this class for similar side effects. "All of the NSAID drugs have risks when taken chronically, especially of gastrointestinal bleeding, but also liver and kidney toxicity. They should only be used continuously under the supervision of a physician."

FDA approved Vioxx in 1999 for the reduction of pain and inflammation caused by osteoarthritis, as well as for acute pain in adults and for the treatment of menstrual pain. It was the second of a new kind of NSAID (Cox-2 selective) approved by FDA. Subsequently, FDA approved Vioxx to treat the signs and symptoms of rheumatoid arthritis in adults and children.

At the time that Vioxx and other Cox-2 selective NSAIDs were approved, it was hoped that they would have a lower risk of gastrointestinal ulcers and bleeding than other NSAIDs (such as ibuprofen and naproxen). Vioxx is the only NSAID demonstrated to have a lower rate of these side effects.

Merck contacted FDA on September 27, 2004, to request a meeting and to advise the agency that the long-term study of Vioxx in patients at increased risk of colon polyps had been halted. Merck and FDA officials met the next day, September 28, and during that meeting the company informed FDA of its decision to remove Vioxx from the market voluntarily.

In June 2000, Merck submitted to FDA a safety study called VIGOR (Vioxx Gastrointestinal Outcomes Research) that found an increased risk of serious cardiovascular events, including heart attacks and strokes, in patients taking Vioxx compared to patients taking naproxen. After reviewing the results of the VIGOR study and other available data from controlled clinical trials, FDA consulted with its Arthritis Advisory Committee in February 2001 regarding the clinical interpretation of this new safety information. In April 2002, FDA implemented labeling changes to reflect the findings from the VIGOR study. The labeling changes included information about the increase in risk of cardiovascular events, including heart attack and stroke.

Recently other studies in patients taking Vioxx have also suggested an increased risk of cardiovascular events. FDA was in the process of carefully reviewing these results, to determine whether further labeling changes were warranted, when Merck informed the agency of the results of the new trial and its decision to withdraw Vioxx from the market.

Additional information about this withdrawal of Vioxx, as well as questions and answers for patients, is available online at http://www.fda.gov/cder/drug/infopage/vioxx/default.htm.

 

For Additional Information, Research under...
Vioxx Side Effects
Effects of Vioxx
Side Effects of Vioxx
Vioxx dosage
Vioxx com
what is Vioxx
Vioxx meningitis
Vioxx 25
Vioxx 25mg
Vioxx drug
drug Vioxx
Vioxx heart
Vioxx celebrex
Vioxx lawsuit
Vioxx alcohol
Vioxx medication
Vioxx class action
Vioxx and meningitis
Vioxx rofecoxib

 

Back to Top

 

Visit Our 2013 NJ Police Training & Schools Section

Mailing List

Receive New Jersey Law Enforcement bulletins
If you would like to receive New Jersey law enforcement
bulletins and/or law enforcement job announcements, click here.

Police and Law Enforcement Home    Advertise    Submit Your Site
Submit Police News   Police Grants    Police Forums    Police News

Copyright 2002-2014-All Rights Reserved  Law Enforcement Media Group - (Not an Official Police Department)    PERC

 

S O C I A L    M E D I A